Business Development
Sirnaomics Establishes a Strategic Partnership with EDIRNA Inc., an RNA-Editing Therapeutic Company
Sirnaomics has established a strategic partnership with EDIRNA Inc. ("EDIRNA"), an early-stage biotech company focused on RNA-Editing therapeutic company, for advancing its proprietary "Edit-to-Cure Therapeutics™" platform, targeting diseases with high unmet clinical need.
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease’s Burdens from Prevention to Cure
Brii Biosciences announced that it has entered into license agreements with VBI Vaccines, Inc. ("VBI", NASDAQ: VBIV), expanding the companies' collaboration in the hepatitis B virus (HBV) field.
Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an antibody license agreement with Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers.
Moderna signs deal in Shanghai with view to developing mRNA medicines
Vaccine maker Moderna Inc (MRNA.O) said on Wednesday it had signed a memorandum of understanding and a land collaboration agreement to work towards opportunities for it to research, develop and manufacture mRNA medicines in China.
Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China
Innovent Biologics (HKEX: 01801) and RemeGen Co. (688331.SH/09995.HK) announced that they entered into a clinical trial collaboration and supply agreement with for the combination therapies of TYVYT® (sintilimab injection) with RC88, a novel mesothelin(MSLN)-targeting antibody-drug conjugate (ADC), or RC108, a novel c-Met-targeting ADC, respectively, as potential treatment options for advanced solid tumors in China.
CereVasc & LianMedical Announce Corporate Partnership
CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, and LianMedical, a medical device company focused on accelerating the introduction of breakthrough medical technologies to markets in Asia, announced today a partnership focused on bringing CereVasc's eShunt® System and related products to patients and providers in China, Hong Kong, Taiwan, and Macaw.
Sanyou Forms Partnership with Hangzhou Zhongmei Huadong Pharmaceutical, Catalyzing Innovative Drug Research and Development
Recently, Sanyou Biopharmaceuticals Co., Ltd. (hereinafter referred to as Sanyou) and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd, a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963) (hereinafter referred to as Huadong Medicine), signed a license agreement for a collaboratively developed therapeutic biological product.
Shineco Enters into Cooperation Agreement with Kangling Medical to Develop New Medical Products Company
Shineco, Inc. (NASDAQ: SISI), announced today that on June 15, 2023, its wholly owned subsidiary, Shineco Life Science Research Co., Ltd. signed a joint venture cooperation agreement with Yangzhou Kangling Medical Co., Ltd. to establish a joint venture company, Shangkang Life Science and Technology.
Pharmadule Morimatsu and WuXi Biologics Reached Global Strategic Partnership
Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics.
Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693
Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, today announced that it entered into definitive agreements with Qpex Biopharma ("Qpex") and third parties in connection with the acquisition of Qpex by Shionogi.
